NT-101 ophthalmic solution for macular degeneration

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 11 Jun 2026: Trial started, NCT07811726
  2. 10 Sep 2026: Trial registered, NCT07811726

The trials

NCT07811726: A Phase 2 Study of NT-101 Topical in Patients With Wet AMD

State
Under way
Phase
Phase 2
People
66 planned
Started
11 Jun 2026
Primary completion
28 Feb 2028
Arms
NT-101 High Dose (0.2 mM)
Results
None posted
  1. 11 Jun 2026: Trial started
  2. 10 Sep 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.